GSK-205724

Study Sponsor: GSK

Study Title

Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)

Medicine or Vaccine (generic name)

danirixin

Sponsor Identification Number

205724

Trial Registry Identification Number(#'s)

NCT03034967 2016-003675-21

Medical Condition

Pulmonary Disease, Chronic Obstructive

Phase

Phase 2

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=205724

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT03034967

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-003675-21

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This study is available in CDISC format.

Date Added to this Site

July 2020